http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
from translational research to next-generation clinical practice
The Science of Glaucoma Management: From Translational Research to Next-Generation Clinical Practice bridges the gap between laboratory research and clinicians by bringing the latest promising research directly from researchers to clinicians long before they translate into clinical advances, and often before they are presented at conferences.
Front Cover -- The Science of Glaucoma Management -- Copyright Page -- Dedication -- Contents -- List of contributors -- Foreword -- Preface -- 1 Currently accepted glaucoma practice -- 1 Glaucoma pathology -- 1.1 Quick reference summary -- 1.2 Introduction to glaucomatous pathology -- 1.2.1 Glaucoma classification -- 1.2.2 Worldwide prevalence -- 1.2.3 The financial burden of glaucoma -- 1.2.4 Risk factors and the continuum of intraocular pressure -- 1.3 Causes of glaucomatous pathology (linking ocular hypertension to optic nerve degeneration) -- 1.3.1 Clinical observations -- 1.3.2 Compression and strain on the optic nerve head -- 1.3.3 Age-related mechanisms -- 1.3.4 Immune mechanisms -- 1.3.5 Vascular mechanisms -- 1.3.6 Translaminar pressure gradient -- 1.3.7 Metabolic mechanisms -- 1.3.8 Glaucomatous pathology at the optic nerve head-a unifying hypothesis -- 1.4 The processes of neurodegeneration -- 1.4.1 Axonal degeneration -- 1.4.2 Dendritic arbor remodeling -- 1.4.3 Neuronal loss by intrinsic apoptosis -- 1.4.4 Signaling of apoptosis in glaucoma -- 1.5 Unmet needs -- References -- 2 Epidemiology of glaucoma -- 2.1 Quick reference summary -- 2.2 Global epidemiology of glaucoma -- 2.3 New trends in glaucoma epidemiology -- 2.3.1 Regional differences in prevalence and the ongoing epidemiological transition -- 2.3.2 Incidence of glaucoma -- 2.3.3 Myopia epidemic and glaucoma -- 2.3.4 Risk factors for primary open-angle glaucoma -- 2.3.4.1 Age -- 2.3.4.2 Race -- 2.3.4.3 Family history -- 2.3.4.4 Intraocular pressure -- 2.3.4.5 Corneal properties -- 2.3.4.6 Optic disk features -- 2.3.4.7 Myopia -- 2.3.4.8 Systemic risk factors -- 2.3.5 Risk factors for primary angle-closure glaucoma -- 2.4 Discussion -- 2.4.1 Implications for current practice -- 2.4.2 The future of glaucoma practice -- References -- 3 Diagnosis and investigations in glaucoma.
3.1 Quick reference summary -- 3.1.1 History -- 3.1.2 Examination -- 3.1.3 OCT -- 3.1.4 Optic nerve head -- 3.1.5 Retinal nerve fiber layer -- 3.1.6 Macula -- 3.1.7 Visual fields -- 3.2 Conclusion -- References -- 4 Follow-up -- 4.1 Quick reference summary -- 4.2 Intraocular pressure and general considerations -- 4.3 Optic nerve head and retinal nerve fiber layer -- 4.4 Visual field -- References -- 5 Glaucoma management -- 5.1 Quick reference summary -- 5.2 Aims of management -- 5.3 Management protocol -- 5.4 First-line treatments -- 5.4.1 Selective laser trabeculoplasty -- 5.4.2 Topical medications -- 5.4.3 Instillation technique and compliance -- 5.5 Surgical options -- 5.6 Angle-closure glaucoma -- References -- 6 Section summary: into the unknown-identifying the needs -- 6.1 Glaucoma detection and screening -- 6.2 Early diagnosis and identification of progression -- 6.3 Pressure-independent treatments -- 6.4 Minimally invasive glaucoma surgery -- 6.5 Pathophysiology and biomarkers -- 6.6 Patient-centered care and personalized medicine -- 2 Pathophysiology and investigation methods -- 7 Considerations for an effective screening program for glaucoma -- 7.1 Quick reference summary -- 7.2 Review of accepted practice -- 7.2.1 Rationale for screening -- 7.2.2 Current consensus -- 7.3 Considerations for an effective screening program -- 7.3.1 World Glaucoma Association Criteria for screening -- 7.3.1.1 Pivotal trials to date -- 7.3.1.2 Validation of screening programs -- 7.3.1.3 Updates in the cost-benefit analysis for glaucoma screening -- 7.3.1.4 Glaucoma screening should not focus on risk factors -- 7.3.1.5 Considerations for a suitable testing strategy -- 7.3.1.6 The challenge with follow-up -- 7.3.2 Novel technologies for glaucoma screening -- 7.3.2.1 Telemedicine screening -- 7.3.2.2 Genetics for screening.
7.3.2.3 Artificial intelligence for screening -- 7.4 Discussion and conclusion -- 7.4.1 Practical recommendations for effective glaucoma screening -- 7.4.2 The future of glaucoma screening practice -- References -- 8 Vascular health and glaucoma -- 8.1 Quick reference summary -- 8.2 Review of the currently accepted knowledge -- 8.2.1 Association between vascular dysfunction and glaucoma -- 8.2.1.1 Vascular risk factors in glaucoma pathogenesis -- 8.2.1.2 Genome-wide association studies -- 8.2.1.3 Preclinical studies -- 8.2.2 Ocular perfusion pressure and ocular blood flow -- 8.2.2.1 Introduction to ocular blood flow and ocular perfusion pressure -- 8.2.2.2 Regulation of ocular blood flow and ocular perfusion pressure -- 8.2.3 Assessment of ocular blood flow and vascular changes -- 8.3 Novel concepts on vascular factors in glaucoma -- 8.3.1 Systemic vascular risk factors for glaucoma -- 8.3.1.1 Blood pressure and glaucoma -- 8.3.1.2 Diabetes and glycemic control -- 8.3.1.3 Hyperlipidemia -- 8.3.1.4 Atherosclerotic disease -- 8.3.1.5 Migraine and vasospasm -- 8.3.2 Management of systemic vascular risk factors and glaucoma -- 8.3.2.1 Antihypertensive use and glaucoma -- 8.3.2.2 Hypoglycemic therapy and glaucoma -- 8.3.2.3 Statin use and glaucoma -- 8.3.3 Ocular blood flow disruptions associated with glaucoma -- 8.3.3.1 Impaired autoregulation in glaucoma -- 8.3.3.2 Disruption of neurovascular coupling -- 8.3.4 Novel approaches to glaucoma diagnosis and management -- 8.3.4.1 Precision medicine-driven targets for optimizing treatment of glaucoma patients based on genetic profile -- 8.3.4.2 Personalization of treatment using chronotherapy/individualized circadian rhythms -- 8.3.4.3 Novel diagnostic tools that consider vascular autoregulation -- 8.3.4.4 Development and evaluation of novel therapeutics that alter perfusion.
8.4 Discussion on current and future implications -- 8.4.1 Choice of treatment for vascular disease and glaucoma -- 8.4.1.1 Management of modifiable vascular risk factors in glaucoma -- 8.4.1.2 Selection of glaucoma medications based on systemic conditions -- 8.4.2 Clinical guidelines for vascular disease management in glaucoma patients -- 8.4.2.1 Defining best practice for treatment of systemic vascular disease in glaucoma patients -- 8.4.2.2 Guidelines for selective glaucoma screening -- 8.4.3 Novel diagnostic and therapeutic tools for vascular health in glaucoma -- 8.5 Conclusion -- References -- 9 The role of circadian and extrinsic intraocular pressure fluctuations -- 9.1 Introduction -- 9.2 Research and technological advancements -- 9.3 Implications in clinical practice -- References -- 10 Pseudoexfoliative glaucoma: epidemiology, pathophysiology, and clinical implications -- 10.1 Quick reference summary -- 10.2 Introduction -- 10.3 Epidemiology -- 10.3.1 Prevalence -- 10.3.2 Incidence -- 10.3.3 Natural history and prognosis -- 10.4 Pathophysiology -- 10.4.1 Etiology -- 10.4.2 Pathogenesis -- 10.4.3 Mechanisms of glaucoma development -- 10.4.4 Biomarker -- 10.5 Clinical implications -- 10.5.1 Diagnosis -- 10.5.2 Management -- 10.5.3 Medical therapy -- 10.5.4 Laser therapy -- 10.5.5 Surgical therapy -- 10.6 Conclusions and perspective -- References -- 11 Angle-closure glaucoma: epidemiology, pathophysiology, and clinical impact -- 11.1 Quick reference summary -- 11.2 Overview -- 11.3 Novel concepts/promising research -- 11.3.1 Epidemiology and pathophysiology -- 11.3.1.1 Genetic biomarkers -- 11.3.1.2 Aqueous humor and blood biomarkers -- 11.3.2 Anterior segment imaging and current understanding of primary angle-closure glaucoma -- 11.3.2.1 Anterior segment optical coherence tomography -- 11.3.2.2 Ultrasound biomicroscopy.
11.3.2.3 Scanning peripheral anterior chamber depth analyzer -- 11.3.2.4 Scheimpflug photography -- 11.3.2.5 Gonio-photographic systems -- 11.3.3 Current evidence on the effectiveness of interventions for primary angle-closure glaucoma disease -- 11.4 Discussion -- 11.4.1 Implications for current practice -- 11.4.2 The future of glaucoma practice -- References -- 12 The role of optical coherence tomography angiography in glaucoma -- 12.1 Quick reference summary -- 12.2 Introduction -- 12.3 Optical coherence tomography angiography in glaucoma -- 12.3.1 Optical coherence tomography angiography scanning regions and parameters of interest in glaucoma -- 12.3.1.1 Optic disk optical coherence tomography angiography scan -- 12.3.1.2 Macular optical coherence tomography angiography scan -- 12.3.1.3 Artifacts in optical coherence tomography angiography imaging -- 12.3.1.4 Optical coherence tomography angiography parameters of interest in glaucoma -- 12.3.1.5 Repeatability and reproducibility -- 12.3.1.6 Factors affecting optical coherence tomography angiography parameters in normal eyes -- 12.3.2 Optical coherence tomography angiography in primary open-angle glaucoma -- 12.3.2.1 Optical coherence tomography angiography in primary open-angle glaucoma diagnosis -- 12.3.2.2 Optical coherence tomography angiography in primary open-angle glaucoma progression -- 12.3.3 Optical coherence tomography angiography in other subtypes of glaucoma -- 12.3.3.1 Normal-tension glaucoma -- 12.3.3.2 Pseudoexfoliation glaucoma -- 12.3.3.3 Primary angle-closure glaucoma -- 12.4 Discussion -- 12.4.1 Implications for current practice -- 12.4.2 Implications for future glaucoma practice -- References -- 13 Structural testing modalities: RNFL, GCIPL, BMO-MRW, or vessel density? -- 13.1 Quick reference summary.
edited by Kevin Gillmann, Kaweh Mansouri.